3 Monster Stocks in the Making to Buy Right Now
CRISPR Therapeutics is still in its early growth stage.
Summit Therapeutics has plenty of upside potential remaining.
Viking Therapeutics is targeting two monster markets.
10 stocks we like better than CRISPR Therapeutics ›
Where can you find the next monster stocks? Check out the biotech space. It's not easy, but investors can sometimes find highly promising biotech stocks that are only in their early innings.
Three Motley Fool contributors think they've identified monster stocks in the making. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX).
Image source: Getty Images.
A promising company in its early growth stage
David Jagielski (CRISPR Therapeutics): Biotech company CRISPR Therapeutics has a market cap of around $5 billion, but it has the potential to be much more valuable in the long run. The gene editing market is still fairly small, but it has a lot of room to grow. Analysts from Grand View Research project that it will expand at a compound annual growth rate of more than 16% between now and 2030, when it will be worth $25 billion. As a leading company in the space, CRISPR Therapeutics is well positioned to benefit from future growth in this area of healthcare.
The company, and its key development partner, Vertex Pharmaceuticals (NASDAQ: VRTX), already have an approved gene therapy treatment in Casgevy, which regulators have approved for both sickle cell disease and transfusion-dependent beta-thalassemia. The companies will share in the profits on the treatment (CRISPR will take 40%). Casgevy is still in its early growth stages. CRISPR is also working on developing treatments for type 1 diabetes and cardiovascular disease. While CRISPR remains unprofitable today, its future does look bright.
It's a long road ahead for CRISPR Therapeutics, but with an encouraging pipeline and a lot of growth potential, this could be a monster healthcare stock in the making. The business is well funded with its cash and marketable securities as of the end of March totaling nearly $1.9 billion, putting it in an excellent position to continue investing in its research and development efforts.
CRISPR can make for an excellent investment, but it's also one you'll need to be patient with.
Still plenty of upside left for this stock
Prosper Junior Bakiny (Summit Therapeutics): Few biotech companies have performed better than Summit Therapeutics over the past three years. The company's shares have soared by more than 2,000%, making early investors who held on significantly wealthier in the process. Here's the good news for those who are still considering the stock: There could be a massive upside left for Summit Therapeutics. Though the biotech generates no revenue and is unprofitable, it has one of the more promising pipeline products in the industry.
Summit Therapeutics' leading candidate is a cancer medicine called ivonescimab, which it licensed out from Akeso Biopharma (OTC: AKES.F), a China-based drug developer.
The medicine has been extensively tested in China, where it has already received approval in certain indications. One of ivonescimab's most promising markets is non-small cell lung cancer (NSCLC). In a phase 3 study in China, it went head-to-head against the market leader and the world's best-selling drug: Merck 's (NYSE: MRK) Keytruda. Ivonescimab emerged victorious, leading to a greater decrease in the risk of recurrence or death among NSCLC patients with a PD-L1 protein overexpression.
Summit Therapeutics is conducting clinical studies to support approval in the U.S. and other regions. Furthermore, the biotech is likely to seek a series of approvals and label expansions over the years, based on the number of clinical trials and indications Akeso is targeting in China. Ivonescimab should easily become a blockbuster and generate strong sales for years. That's why it's not too late to invest in Summit Therapeutics. If ivonescimab achieves its full potential, Summit could deliver market-beating returns in the next five to 10 years and establish itself as a prominent player in the biotech industry.
Targeting two monster markets
Keith Speights (Viking Therapeutics): The big story for Viking Therapeutics is its experimental obesity drug VK2735. The company recently advanced a subcutaneous formulation of this candidate into late-stage clinical testing after announcing highly encouraging results from a phase 2 study last year.
Viking is also evaluating an oral version of VK2735 in a separate phase 2 clinical trial, and it expects to report results from that study later in 2025. In addition, the drugmaker plans to initiate a clinical study for a monthly maintenance version of subcutaneous VK2735 in the coming months.
Morgan Stanley Research projects that the global obesity drug market could reach $150 billion by 2035. Viking could be in a great position to claim a nice chunk of that market if VK2735 fulfills its potential.
Obesity isn't the only big market that the company is targeting, though. In 2023, Viking reported positive results from a phase 2 study of VK2809 in treating metabolic-associated steatohepatitis (MASH), a chronic liver disease also known as nonalcoholic steatohepatitis (NASH). The company is seeking a partner to advance VK2809 into late-stage testing, so it can dedicate its financial resources exclusively to VK2735 for now. Grand View Research predicts the MASH/NASH market could hit $33.8 billion by 2030, so that's a nice opportunity.
A clinical trial flop for VK2735 and/or a failure to find a partner for VK2809 could prevent Viking from becoming a monster stock. However, I think the company's chances look pretty good. I also wouldn't be surprised if a larger drugmaker swoops in to acquire Viking.
Should you invest $1,000 in CRISPR Therapeutics right now?
Before you buy stock in CRISPR Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!*
Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 15, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
5 hours ago
- Globe and Mail
Nasdaq Q2 Revenue Jumps 13 Percent
Key Points - Nasdaq (NASDAQ:NDAQ) beat both GAAP revenue and non-GAAP earnings expectations in Q2 2025, posting double-digit growth in recurring revenues and non-GAAP operating income. - Record results in Market Services and robust client demand in both Financial Technology and Capital Access Platforms were key strengths this period. - The company raised its quarterly dividend to $0.27 per share in Q2 2025, updated its 2025 non-GAAP operating expense guidance to a range of $2,295 million to $2,335 million, and maintained its 2025 non-GAAP tax rate guidance, while highlighting increased investment costs and regulatory-driven sales cycle delays. These 10 stocks could mint the next wave of millionaires › Nasdaq (NASDAQ:NDAQ), a global technology company powering capital markets and financial services, reported its Q2 2025 results on July 24, 2025. The company delivered GAAP revenue of $1.31 billion and non-GAAP earnings per share (EPS) of $0.85, both surpassing consensus estimates of $1.28 billion and $0.81, respectively. Recurring revenue grew 9% and operating income (non-GAAP) grew at a double-digit rate, driven by strong client demand and innovations across both its Financial Technology and Capital Access Platforms. Overall, the quarter showed operational progress, though rising costs and lengthening sales cycles in regulatory technology signal areas to watch going forward. Source: Analyst estimates for the quarter provided by FactSet. Business Overview and Focus Areas Nasdaq operates at the intersection of technology and finance. It is best known for running the Nasdaq Stock Market, but its reach extends to providing trading, data, software, and analytics to financial institutions and corporations worldwide. Nasdaq manages and provides its products and services through three business segments: Capital Access Platforms, Financial Technology, and Market Services. The stack of offerings ranges from traditional exchange listing and trading to modern SaaS (software-as-a-service) platforms that help banks and corporates manage everything from regulatory compliance to market analytics and risk surveillance. Over the past few years, the company emphasized steady recurring revenue, cloud and AI innovation, and international expansion. Recent strategic focus includes deepening cloud integration, boosting cross-selling after its Adenza acquisition, and increasing the share of SaaS in its recurring revenue streams. Key drivers of success remain technology leadership, robust regulatory compliance capabilities, and the ability to attract new clients through innovation and trusted infrastructure. Quarter Review: Results, Product Momentum, and Segment Detail The second quarter saw Nasdaq achieve broad-based growth and notable outperformance across its main business lines. Revenue and Profits: The revenue figure of $1.31 billion (GAAP) represented a 13% jump over the same period last year. Non-GAAP EPS came in at $0.85, up 24% over the prior year, while operating income grew by 16%. Non-GAAP operating margin also edged higher, from 53% to 55%. This indicates that the company achieved greater efficiency, even as it invested in new technology and talent. Solutions Segment: Solutions revenue—which covers both Capital Access Platforms and Financial Technology—grew 10% year-over-year, with both core sub-segments making strong contributions. Financial Technology: This segment includes cloud-based risk, compliance, and trading solutions. It recorded 10% growth in revenue, with annualized recurring revenue (ARR) for Financial Technology growing 12% year-over-year. Regulatory Technology made progress with a new large client and several upsells, but did note extended sales cycles due to shifting U.S. regulatory timelines. Capital Access Platforms: This product line includes listing-related data, workflow, and index solutions. It posted 9% organic revenue growth, driven by a 17% rise in Index revenue. Net inflows into Nasdaq-linked exchange-traded products (ETPs) totaled $20 billion, and the number of ETPs tracking the company's indices increased sharply. Market Services: This unit, which comprises trading platforms and associated services, delivered a record $306 million in net revenue, an increase of 22%. Volumes across U.S. equities and derivatives hit all-time highs, and the company reported its 46th straight quarter of leadership in IPO listings, with 38 new operating company IPOs raising more than $3.5 billion. Market share for U.S.-listed securities, combining on- and off-exchange activity, hit 61.6%, up from 59.0% in Q2 2024. Recurring Revenue and SaaS Growth: Annualized recurring revenue reached $2.93 billion, which is 10% above the prior year. Of this, 37% now comes from SaaS products. Expenses and Margins: Operating expenses on a non-GAAP basis rose 9%, largely reflecting increased investments in technology and people. But with revenues advancing even faster in some segments, non-GAAP margins still improved. Product and Innovation: Technological innovation was a central theme this quarter. Nasdaq Verafin's 'Agentic AI' digital workers, now in beta, promise to automate compliance reviews and lower client workload. The company also expanded its partnership with Amazon Web Services (AWS) for cloud-based market infrastructure. Recent technology wins include managed marketplace deployments and cloud-based platform launches for clients in Latin America. Capital Strategy and Shareholder Returns: The company continued to emphasize a focus on organic growth and deleveraging after the large 2023 Adenza acquisition. During the quarter, it returned $155 million to shareholders via dividends and $100 million through stock buybacks, and repaid $400 million of debt. Management reaffirmed its goal of more than $100 million in annual run-rate cross-sell revenue by the end of 2027. Dividend Update: The company raised its quarterly dividend by 13% to $0.27 per share, continuing its trend of regular increases. Looking Ahead: Management Outlook and Watch Items Management maintained non-GAAP operating expense guidance, now at $2.295–$2.335 billion for FY2025, reflecting minor foreign exchange effects but otherwise an unchanged outlook. Non-GAAP tax rate guidance for 2025 remains at 22.5%–24.5%. No change was announced to medium-term revenue growth targets in any segment for FY2025, with leaders expressing confidence in the current sales pipeline, especially for Financial Technology products. No explicit top-line or EPS guidance was shared for the full year. Delays in regulatory technology sales cycles, driven by shifting U.S. regulatory timelines, present a risk to growth. Intensifying competition from both established exchanges and new entrants—like the Texas Stock Exchange—remains on the radar for listings market share. Overall, Nasdaq credited broad client engagement, cloud and AI innovation, and a stable recurring revenue base as tailwinds for future performance. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,037%* — a market-crushing outperformance compared to 182% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of July 21, 2025
Globe and Mail
6 hours ago
- Globe and Mail
Altisource Q2 Revenue Up 11 Percent
Key Points - Revenue (GAAP) rose 11% to $43.3 million in Q2 2025, reflecting year-over-year improvement in Adjusted EBITDA across both major business segments. - Net income turned positive at $16.6 million, driven by an $18.5 million one-time tax reserve reversal for India in Q2 2025. - But underlying operating cash flow (non-GAAP) remained negative. These 10 stocks could mint the next wave of millionaires › Altisource Portfolio Solutions (NASDAQ:ASPS), a provider of services and technology for the mortgage and real estate industries, published its Q2 2025 earnings on July 24, 2025. The most notable news was a sharp swing to positive net income (GAAP), largely due to a substantial tax benefit from reversing reserves tied to prior uncertainties with Indian tax positions. Revenue climbed 11% to $43.3 million, up from $39.1 million in the same quarter last year, with adjusted EBITDA (non-GAAP) rising 23% to $5.4 million. With no available analyst consensus, it is not possible to gauge this quarter's results against Street expectations. Overall, the second quarter showed stronger service revenue and profitability compared to the same period in 2024, but the headline numbers were heavily influenced by non-operational gains and persistent cash outflows. Metric Q2 2025 Q2 2024 Y/Y Change Diluted EPS (GAAP) $1.48 ($2.33) $1.86 Adjusted Diluted EPS (Non-GAAP) $0.19 ($1.67) — Revenue (GAAP) $43.3 million $39.1 million 11% Adjusted EBITDA (Non-GAAP) $5.4 million $4.4 million 23% Net Income (GAAP) $16.6 million ($8.3 million) $24.9 million Business Overview and Strategic Focus Altisource is a specialized services and technology company concentrated in the mortgage, real estate, and loan origination markets. It offers a portfolio of technology platforms and business process services supporting mortgage servicing, property management, and mortgage origination. Key product lines include technology solutions such as Equator, a loan servicing platform, and RentRange, which provides data analytics for real estate investment. Its growth strategy depends on deep relationships with major clients, technology-enabled solutions, and effective management of debt and overall financial leverage. One customer, Onity, accounts for a substantial portion of revenue, leading to client concentration risk. The company also emphasizes innovation in software-as-a-service (SaaS) and automation, while actively managing debt and seeking opportunities in evolving regulatory and market conditions. Quarter Highlights: Revenue Growth, One-Off Gains, and Debt Moves During Q2 2025, Altisource saw service revenue rise 11%, supported by improvements in Adjusted EBITDA in both the Servicer and Real Estate, and Origination segments. Service revenue increased by $3.9 million year over year, Segment-level margins increased slightly. However, gross margin on service revenue dipped from 34% in Q2 2024 to 32% in Q2 2025 (GAAP). This decline occurred despite top-line growth. The most significant profit driver was the $18.5 million reversal of reserves related to uncertain Indian tax positions, including $9.6 million for taxes and $9.0 million for accrued interest. This non-operational item transformed the company's net income for the period; without it, adjusted net income would have been much lower at $2.2 million (non-GAAP). Excluding this effect, adjusted diluted earnings per share (non-GAAP) moved to $0.19 from a loss a year earlier, demonstrating improvement, but on a much smaller scale than the GAAP figures. Debt reduction and restructuring were also major features. After a term loan exchange in Q1 2025, long-term debt consisted of a $160.0 million senior secured term loan and a $12.5 million super senior term loan, compared to $232.8 million at the end of 2024, aided by a $12.5 million Super Senior facility and $45.4 million in equity issued in exchange for debt. Net debt (non-GAAP) at quarter end was $142.2 million. This reduction is expected to lower annual GAAP interest expense to approximately $9.5 million, creating future savings in cash flow and improving the balance sheet. The company also implemented a 1-for-8 reverse stock split on May 28, reducing shares outstanding and altering share price dynamics. Despite the positive headline results, operating cash flow (GAAP) remained negative at ($0.3) million for the quarter and ($5.3) million for the first six months of 2025. Negative cash flow from operations (GAAP) signals continued pressure on the ability to fund future investments internally, even as the company works to stabilize its financial base. Corporate and other segment losses offset improvements in the main business lines, underscoring ongoing challenges with cost discipline outside core operating units. No dividend was declared or paid during the quarter. ASPS does not currently pay a dividend. Industry and Market Context Market conditions during the quarter shaped Altisource's growth in important ways. The broader mortgage industry saw a modest pickup: foreclosure initiations were up 22% for the five months ended May 31, 2025 compared to the same period in 2024, but volumes remain well below pre-pandemic levels, with foreclosure initiations still 22% lower than in 2019 and foreclosure sales 51% below that benchmark for the same period. Mortgage origination volumes rose 14% for the six months ended June 30, 2025 compared to the same period in 2024, driven mainly by a 58 % jump in refinancing activity, while purchase activity fell slightly. However, management noted that the current environment remains 'close to historically low' in terms of industry delinquencies, continuing to constrain organic growth for foreclosure- and default-related services, as referenced in recent disclosures. The company reported some wins in new business during the period, estimating annualized stabilized service revenue from sales wins of $1.1 million in its Servicer and Real Estate business and $3.3 million in Origination. Technology remains a central theme, but the company reported no quantitative progress on platforms like Equator or in SaaS adoption metrics. Management continues to describe technology-enabled solutions as an area of focus, yet offered no new data to measure this area's contribution during the period. Regulatory factors impacted results through the tax reversal in India—removing significant uncertainty and legal overhang. Though management underscored that regulation remains an ever-present aspect of operating in the mortgage and real estate services sector. Outlook and What to Watch Management offered no explicit financial guidance for the next quarter or the full year. Executives highlighted their expectation that higher industry defaults and foreclosure volumes would boost results in Altisource's most profitable business lines. They noted a weighted average sales pipeline between $36 million and $44 million in potential annualized service revenue, with the majority of future opportunities likely to be realized in 2026 and beyond. The company remains focused on growing business lines with favorable industry trends, managing costs, and building financial flexibility following the recent debt restructuring. Investors may want to monitor whether operating cash flow can turn positive, how well sales pipeline wins convert to recurring revenues, and any changes in client concentration or major contract renewals. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,037%* — a market-crushing outperformance compared to 182% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of July 21, 2025 JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Globe and Mail
7 hours ago
- Globe and Mail
Absci Announces Pricing of Public Offering of Common Stock
VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) ('Absci'), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, today announced the pricing of an underwritten public offering of 16,670,000 shares of its common stock at a public offering price of $3.00 per share, before deducting underwriting discounts and commissions. In addition, Absci has granted the underwriters a 30-day option to purchase up to an additional 2,500,500 shares of its common stock on the same terms and conditions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Absci. Absci intends to use the net proceeds from the offering to fund the advancement of its internally developed programs, continued investment in its Integrated Drug Creation™ platform, and for working capital and other general corporate purposes. Morgan Stanley, J.P. Morgan, Jefferies, and TD Cowen are acting as joint book-running managers for the offering. The offering is expected to close on or about July 25, 2025, subject to the satisfaction of customary closing conditions. The shares of common stock are being offered by Absci pursuant to an effective shelf registration statement on Form S-3 (File No. 333-267043) that was previously filed with the U.S. Securities and Exchange Commission (SEC) on August 24, 2022 and became effective on September 2, 2022. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on July 24, 2025. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone: (866) 718-1649, or by email at prospectus@ J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@ and postsalemanualrequests@ Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at prospectus_department@ TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (833) 297- 2926, or by email at or by accessing the SEC's website at This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Absci Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Absci's anticipated public offering. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, such as the intended offering terms, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions, statements about the expected gross proceeds from the offering and use of proceeds, and the completion of the offering on the anticipated terms or at all. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Absci's Annual Report on Form 10-K for the year ended December 31, 2024, as amended, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Absci's other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the public offering filed with the SEC. In addition, any forward-looking statements contained in this press release represent Absci's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Absci explicitly disclaims any obligation to update any forward-looking statements, except as required by law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
